In the past week, GHRS stock has gone up by 10.94%, with a monthly gain of 35.73% and a quarterly surge of 21.50%. The volatility ratio for the week is 7.25%, and the volatility levels for the last 30 days are 4.86% for GH Research PLC The simple moving average for the past 20 days is 14.95% for GHRS’s stock, with a 42.02% simple moving average for the past 200 days.
Is It Worth Investing in GH Research PLC (NASDAQ: GHRS) Right Now?
Additionally, the 36-month beta value for GHRS is 0.98. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for GHRS is 39.52M and currently, short sellers hold a 7.23% ratio of that float. The average trading volume of GHRS on June 12, 2025 was 180.73K shares.
GHRS) stock’s latest price update
GH Research PLC (NASDAQ: GHRS)’s stock price has gone rise by 7.40 in comparison to its previous close of 12.84, however, the company has experienced a 10.94% increase in its stock price over the last five trading days. globenewswire.com reported 2025-05-15 that DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a Pharmaceutical Pipeline Presentation at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP) in Arizona, United States from May 27 – 30, where Professor Michael E. Thase, MD, Professor of Psychiatry, Perelman School of Medicine, University of Pennsylvania will present clinical data from a randomized, double-blind, placebo-controlled Phase 2b clinical trial with GH001 in patients with treatment-resistant depression (TRD) (GH001-TRD-201).
Analysts’ Opinion of GHRS
Many brokerage firms have already submitted their reports for GHRS stocks, with Cantor Fitzgerald repeating the rating for GHRS by listing it as a “Overweight.” The predicted price for GHRS in the upcoming period, according to Cantor Fitzgerald is $25 based on the research report published on June 04, 2025 of the current year 2025.
Guggenheim, on the other hand, stated in their research note that they expect to see GHRS reach a price target of $32. The rating they have provided for GHRS stocks is “Buy” according to the report published on March 13th, 2025.
RBC Capital Mkts gave a rating of “Outperform” to GHRS, setting the target price at $31 in the report published on March 07th of the current year.
GHRS Trading at 29.57% from the 50-Day Moving Average
After a stumble in the market that brought GHRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.73% of loss for the given period.
#####
#####
Stock Fundamentals for GHRS
The total capital return value is set at -0.17. Equity return is now at value -16.20, with -15.65 for asset returns.
Based on GH Research PLC (GHRS), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -62.71. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -94.01.
Currently, EBITDA for the company is -37.93 million with net debt to EBITDA at 5.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 29.71.
Conclusion
In conclusion, GH Research PLC (GHRS) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
